Background: Succinate dehydrogenase subunit B (SDHB) immunohistochemistry was considered a valuable tool to identify patients with inherited
| INTRODUCTION
Paragangliomas (PGLs) originate from the neural crest-derived chromaffin cells of the sympathetic or parasympathetic system. Sympathetic paragangliomas (pheochromocytomas [PCCs]/ PGLs) arise from the adrenal gland (PCCs) or from the diffuse paraganglional system in the abdomen or thorax (PGLs). Parasympathetic head and neck paragangliomas (HNPGLs) are mainly located in the head and neck region and originate from the carotid body or the jugular, tympanic, or vagal glomus.
To date, germline mutations in different genes have been associated with development of syndromic presentation of both HNPGLs and PCCs/PGLs. In sporadic forms, these same mutations can also be present at the somatic, not germline, level. Known susceptibility genes are succinate dehydrogenase B, D, C, and A (collectively SDHx genes) and SDH complex assembly factor 2 (SDHAF2) in familial PGL syndromes, the RET proto-oncogene in multiple endocrine neoplasia type 2, VHL and NF1 in the von Hippel Lindau and neurofibromatosis syndromes, respectively, and PHD2/EGLN1, TMEM127, MAX, FH, MDH2, and EPAS1 (see Refs. 1 and 2 for recent reviews). Somatically mutated driver genes include HRAS, RET, EPAS1, VHL, ATRX, NF1, CSDE1, and fusion genes involving MAML3, BRAF, NGFR, and NF1. [3] [4] [5] [6] [7] [8] [9] [10] Given the high number of genes associated with the development of HNPGLs/PCCs/PGLs, it is important to develop efficient and simple strategies to prioritize the genetic analysis of some genes over others. In the case of HNPGLs, most inherited tumors are associated with mutations in SDHx genes. Recent relevant studies have shown that absence of immunohistochemical detection of succinate dehydrogenase subunit B (SDHB) or of both SDHB and succinate dehydrogenase subunit A (SDHA) is associated with mutational inactivation of SDHB, D, C, A genes or the SDHA gene, respectively, in HNPGLs/PCCs/PGLs [11] [12] [13] [14] [15] [16] [17] [18] [19] and other types of cancers. [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] However, most reported data on HNPGLs/PCCs/PGLs have not made distinctions on whether the tumors are derived from the sympathetic or the parasympathetic lineage, even though it has long been widely recognized that the 2 types of tumors differ in clinical behavior and have different genetic, biochemical, and molecular features. For example, HNPGLs rarely secrete catecholamines, whereas almost all PCCs/PGLs are biochemically active; malignancy is more frequently observed in PCCs/PGLs than in HNPGLs; and some susceptibility genes, such as VHL, RET, MAX, and FH, have been rarely, or never, associated with HNPGLs. Furthermore, recent microarray data have shown differences between SDHDassociated HNPGLs and SDHD-associated PCCs/PGLs, suggesting that, although both types of tumors are related to the same pathogenic gene, they develop via different mechanisms. 34 The role of the hypoxic inducible factor 1α (HIF-1α) on the pathogenesis of HNPGLs or PCCs/PGLs is also under debate [35] [36] [37] [38] and, although SDH deficiency has been shown to trigger HIF-1α stabilization, the value of HIF-1α protein as a clinical biomarker is still unknown. Based on this knowledge, we have directed the present study to describe common and different features of HNPGLs and PCCs/PGLs diagnosed in a cohort of Spanish patients. Specifically, SDHB, SDHA, and HIF-1α protein expression have been analyzed in relationship with clinical data and genetic background.
| MATERIALS AND METHODS

| Tumor specimens
Tumor samples were obtained from 158 patients with HNPGLs and PCCs/PGLs, diagnosed and treated between 1996 and 2016 at the Hospital Universitario Central de Asturias, Hospital Gregorio Marañón, Hospital Provincial de Castellón, Hospital General Virgen de la Luz, Hospital Virgen del Rocío, Hospital Universitario Araba-Txagorritxu, Complejo Hospitalario de Navarra, Hospital Universitario de Bellvitge, and Hospital Clinic of Barcelona. Tumor samples included 156 primary tumors and 2 metastases (Table 1) . Informed consent was obtained from each patient. The study was approved by the Ethical Committee of the Hospital Central of Asturias, and the study methods were carried out in accordance with the approved guidelines and the principles expressed in the Declaration of Helsinki. Clinical data were collected from patients' medical reports. Median follow-up of patients was 7 years.
| Mutation analysis
Genomic DNA was isolated using the QIAmp DNA Mini kit (Qiagen, Chatsworth, CA) and subsequently treated with RNase A (1 unit/mL) at 37 C for 5 minutes. Mutation analysis of genes was performed by direct sequencing, as previously described. 36 Mutation analyses of SDHB, SDHC, SDHD, and VHL genes in blood DNA was performed in all patients included in this study. The VHL, NF1, and RET genes were analyzed in blood samples from patients with clinical manifestations suggestive of inherited syndromes (n = 7) or, in the case of the RET gene, also if the patients had predominantly elevated metanephrines. Analysis of somatic VHL mutations has been previously reported for 53 HNPGLs. 35, 39 The VHL gene was analyzed for the presence of large deletions in tumor DNA using the multiplex ligation-dependent probe amplification (MLPA; SALSA MLPA P016, MRC Holland) method, as recommended by the manufacturer. The MLPA P226 was used for the analysis of SDHD, SDHB, and SDHC large deletions in all patients included in the study.
| Immunostainings
The SDHB, SDHA, and HIF-1α expressions were evaluated by immunohistochemistry in tissue sections, as previously described. 35 Staining intensity, scored from 1 to 3+, was multiplied by the percentage of stained cells to obtain an immunoscore. Positivity was exclusively found in the nuclei, never in the cytoplasm, of cancer cells and in the vascular endothelia, which was used as an internal positive control. Images were analyzed randomly by 3 of the authors (A.A., C.S., and M.D.C.) without knowledge of clinicopathological data.
| Statistical analysis
All statistical analyses were performed using SPSS statistical software version 19 (SPSS, Chicago, IL), as previously described. 39 Any P values < .05 was defined as statistically significant.
| RESULTS
| Clinical and genetic features of HNPGLs and PCCs/PGLs
Tumor sections from 158 patients were included in this study. Their clinical data are described in Figure 1 ). Similar associations were found when the analysis included only HNPGLs or PCCs/ PGLs (P < .0001; Table 3 ). Clinical data regarding family history of PGLs was available for 86 patients with HNPGLs.
A positive family history of PGLs was present in 18% of patients (16/86). As shown in Table 3 , the fraction of patients with SDHx mutations that could have been identified by considering only family history of PGLs is very low (37% with a 95% CI of 23 to 53) as compared to the sensitivity of the SDHB immunohistochemical test. There were 14 of 70 negatively immunostained tumors that lacked germline SDHx mutations. These samples were positively immunostained for SDHA, thus ruling out the presence of SDHA mutations (representative example shown in Figure 2B ). Remarkably, this group of tumors included the only 3 samples (2 PCCs and 1 HNPGL) with VHL mutations included in our series. Another sample carried an SDHB variant (p.S163P), that has been previously considered as not pathogenic, 44 and the other case corresponds to a tumor that carries SDHC epigenetic silencing in the absence of other PCC/PGL-related gene mutations. 45 Thus, SDHB immunonegativity might occur in tumors from patients carrying mutations in VHL but not in SDHx genes or in tumors with SDHC hypermethylation. For the rest of the tumors, the mechanism involved in the absence of SDHB immunostaining remains unknown. Genetic analysis at the somatic level (SDHx gene sequencing, MLPA, and analysis of methylation of the SDHC promoter) could reveal the presence of noninherited SDHx deregulations that explain the absence of SDHB immunostaining in some tumors. Tumor DNA was only available for 3 of those tumors and it was used for analysis of SDHC promoter methylation, which was found unmethylated. We also found 3 samples with SDHB immunopositivity in patients carrying germline SDHx mutations (see Figure 2B for a representative example). Remarkably, twothirds of the samples were SDHD-mutated or had a family history of PCC/PGLs (Figure 2A ). In these cases, immunostaining was found to be weak but punctate as expected for mitochondria immunodetection. Therefore, based on both positive family history and SDHB immunohistochemical data, the probability of missing genetic diagnosis in patients with SDHx mutations was low: 1 of 60 patients (1.6%) with available data about family history and SDHB immunohistochemistry had absence of a family history and weak immunopositivity of SDHB in the presence of germline SDHx mutation. Besides these cases, SDHB immunopositivity was also found in a metastatic PCC that carried a variant (p. H50R) of the SDHD gene, previously described as a nonpathogenic polymorphism. 46 This patient lacked germline mutations in SDHB, SDHC, SDHA, SDHAF2, RET, or VHL.
In HNPGLs but not in PCCs/PGLs negative SDHB immunostaining correlated with multiple tumors (P = .007), male sex (P = .018), and early age at diagnosis (P = .017). An association with metastatic disease was found in the PCCs/PGLs subgroup of tumors (P = .008) but not in HNPGLs (P = .544; Table 4 ). No other significant associations were found in PCCs/PGLs.
Negative SDHA immunostaining was only found in 1 patient carrying an SDHA mutation (c.1334C>T; p. S445L). This mutation has not been previously reported.
| HIF-1α immunohistochemical data: Relationships with SDHx mutations and clinical data
About 52% of tumors had some positive immunostained cells, an event that was more frequently found in HNPGLs (63% of tumors) than in PCCs/PGLs (26% of tumors). The HIF-1α immunoscore, defined as the percentage of immunostained cells per staining intensity, ranged from 0%-210% and it was significantly higher in HNPGLs (34 ± 50) than in PGLs/PCCs (7 ± 29; P = .001). Subsequent analyses were performed independently in the 2 groups of tumors (Table 5 and Figure 3 ).
In HNPGLs, higher HIF-1α immunoscores were found in tumors harboring SDHx mutations versus non-SDHx mutants (P = .020; Table 5 ). By contrast, no significant differences of HIF-1α immunoscores were found between tumors with or without SDHx mutations (P = .319) in PCC/PGLs. When the median HIF-1α immunoscore value (24) was selected as the cutoff to define highly immunostained samples (above the cutoff ) and weakly immunostained samples (below the cutoff ), high staining of HIF-1α was detected in 53% of SDHx HNPGLs and 19% of nonSDHx HNPGLs. Although the differences were statistically significant (P = .003), about 47% of the SDHx HNPGLs had an HIF-1α immunoscore <24, and 25% SDHx HNPGLs lacked any HIF-1α immunopositive cell, thus raising into question the value of HIF-1α immunohistochemistry as a biomarker of SDHx HNPGLs.
Analysis of the relationships of HIF-1α immunostaining with clinical data revealed that HIF-1α protein accumulation was not different in benign versus malignant primary HNPGLs or PCCs/PGLs (P = .915 and P = .249, respectively). Moreover, the 2 abdominal metastatic tissues included in this study displayed absence of HIF-1α positive nuclei. The HIF-1α expression levels were not associated with other clinical variables, such as tumor location, multiple tumors, sex, or age at diagnosis in HNPGLs and in PCCs/ PGLs (Table 5 ). Table 6 shows the relationship between SDHB and HIF-1α protein expression as detected by immunohistochemistry. Higher HIF-1α protein levels were found in tumors with SDHB-negative immunostainings than in SDHBpositive tumors but the differences were not statistically significant (P = .078). In PCCs/PGLs, no significant differences of HIF-1α immunoscores were found between tumors with negative or positive SDHB immunostaining (P = .288).
| Relationships of SDHB and HIF-1α immunostainings
| DISCUSSION
This study evaluated the clinical relevance of combined genetic and immunohistochemical data related to SDH dysfunction based on an analysis of the largest reported series of HNPGLs. 11, 12, 16, 43 It also provides novel data regarding the relationship of SDH deficiency and upregulation of HIF-1α in HNPGLs versus PCCs/PGLs. The series of patients used in this study have clinical features that resemble those of other published series with regard to age of onset and development of multifocal tumors In agreement with previous studies in paraganglionic tumors, 16 SDHB immunostaining showed similar sensitivity and specificity in PCCs/PGLs and HNPGLs to select patients with a risk of having germline SDHx mutations. Remarkably, the predictive value of SDHB immunohistochemistry for identification of patients carrying germline SDHx mutations was superior to a positive family history; therefore, this histopathological test should be included in the portfolio of clinical management of HNPGLs and PCCs/ PGLs as a classifier to identify patients who have to be subjected to genetic tests of SDHx.
A drawback of SDHB immunohistochemistry as a reliable method for identification of carriers of SDHx mutations is the possibility of missing the diagnosis of hereditary disease in about 5% of cases, when SDHB immunohistochemistry is evaluated as positive but the patient still carries an SDHx mutation. Interestingly, 3 of 4 cases identified with that molecular profile in our series had SDHD mutations and weak granular immunostaining. These observations have been reported in some patients with SDHD-mutated PGLs 43 but in only 1 of those cases the identified SDHD mutation was identical to 1 mutation found in our study (p.H50R). In that study, the authors concluded that positivity of immunohistochemistry confirms a previous study in supporting the idea that the p.H50R variant is a rare polymorphisms rather than a pathogenic mutation. 42 Because the patient included in our study developed a metastatic PCC that was diagnosed 4 months after surgical resection of the primary tumor, and other pathogenic mutations in RET, SDHB/C/AF2, TMEM127 were not identified, the data suggest the possibility that the p.H50R mutation may increase the susceptibility for developing PGLs, even in its metastatic form. It is also possible that other somatic mutations, not explored here, are Another aspect of interest for researchers in the field is that our study, like others, showed that SDHB immunostaining can be evaluated as negative in patients lacking SDHx mutations (n = 14 cases). Three of such patients identified in our study carried germline (n = 2) or somatic (n = 1) VHL mutations. Therefore, we suggest that negative SDHB immunostaining could be useful to select patients to study the VHL gene if the clinical data suggest this disease or a previous study of SDHx mutations was negative. We previously reported an association between partial loss of SDHB protein and somatic VHL mutations in HNPGLs. 40 The present study extended the previous results to PCCs/PGLs. Specifically, 2 of 2 VHL-mutated PCCs/PGLs in our series displayed negative SDHB immunostaining. This association has been reported previously in PCC/PGLs. 12, 16, 36, 40 However, the mechanisms involved in attenuation of SDHB Abbreviations: HNPGL, head and neck paraganglioma; PCC, pheochromocytoma; PGL, paraganglioma; SDH, succinate dehydrogenase. a Somatic mutation. Abbreviations: HIF, hypoxia-inducible factor; HNPGL, head and neck paraganglioma; PCC, pheochromocytoma; PGL, paraganglioma.
protein levels and the relevance of its interplay with VHL gene deficiency is presently unclear. A putative role of the HIF-1α target microRNA, miR-210, has been proposed for HNPGLs 40 but, thus far, its role has not been proven for sympathetic PCCs/PGLs. Because fewer than 5% of tumor cells in the VHL-mutated PCCs/PGLs showed positive HIF-1α immunostaining, the involvement of the HIF-1α/miR-210 pathway in the silencing of SDHB protein expression is questionable. Our data also suggest that, besides VHL gene structural alterations, other mechanisms are involved in the SDHB silencing in the absence of germline SDHx and VHL mutations. One possibility is methylation of the SDHC gene, which has been identified in 1 of the HNPGLs 45 similarly to other tumors of the Carney syndrome. 48 In addition, mutations of SDHx genes at the somatic level, although not frequent in HNPGLs, could explain the absence of SDHB protein in some of the tumors. Thus, the study of tumor DNA from SDHBnegatively immunostained tumors will be warranted in patients if they lack germline mutations in SDHx and VHL genes and if new therapeutic options tailored to patients with SDH-deficient tumors are identified. In this report, we have also analyzed HIF-1α protein expression based on the hypothesis linking SDHx deficiency and HIF-1α activation to the pathogenesis of SDHx tumors. Importantly, we have found differences with regard to the lineage of origin of the paraganglionic tumors (ie, parasympathetic or sympathetic). The HIF-1α protein was found to accumulate in a very small percentage of tumor cells in both types of tumors, HNPGLs and PCCs/PGLs, but the immunoscore of detectable HIF-1α was higher in HNPGLs than in PCCs/PGLs. Furthermore, although HIF-1α positivity in HNPGLs was significantly associated with the presence of SDHx mutations and it had a higher immunoscore in SDHB- immunonegative than immunopositive tumors in accordance with a previous report, 35 this association was not found in
PCCs/PGLs. It should be emphasized, however, that about 47% of SDHx-mutated HNPGLs have <24% of positive HIF-1α tumor cells, thus suggesting that accumulation of HIF-1α is not an early event in the development of SDHxmutated HNPGLs and that it is not a useful biomarker for the identification of SDHx-mutation carriers. It is possible that SDHx mutations trigger the growth of paraganglionic cells via HIF-1α-independent mechanisms and favor an intracellular microenvironment that, only when it reaches a threshold level, triggers HIF-1α protein accumulation. Parasympathetic cells in HNPGLs are likely more prone to respond to that altered intracellular microenvironment than sympathetic cells. This provides an explanation for the published contradictory data regarding the link between SDH dysfunction and HIF-1α. 36, 40, 49 In this study, data about HIF-2α protein levels in tumors are not reported because the immunohistochemical analysis using 2 different commercially available HIF-2α antibodies yielded unreliable results with cytoplasmic rather than nuclear immunostaining (unpublished data). In summary, our data support the notion that, as previously reported for PCCs/PGLs, SDHB and SDHA immunohistochemistry are valuable tools in HNPGLs to prioritize the study of SDHx germline mutations. Nevertheless, care should be taken with cases with weak granular staining because they could be associated with germline SDHD mutations. We also stress the fact that a study of SDHx mutations may be negative in about 20% of patients with negative SDHB immunostaining given that other not well-understood mechanisms or SDHx deregulations at the somatic levels may silence SDHB protein expression. We have also shown that although SDHx mutations may favor HIF-1α stabilization in HNPGLs but not in PCCs/PGLs, it seems that it is not an early event required for the development of these tumors. Thus, our data suggest uncertainty about therapeutic effectiveness of targeting HIF-1α in HNPGLs or PCCs/PGLs and rule out the usefulness of HIF-1α immunostaining as a clinically significant biomarker in patients with HNPGLs or PCCs/PGLs. Abbreviations: HIF, hypoxia-inducible factor; HNPGL, head and neck paraganglioma; PCC, pheochromocytoma; PGL, paraganglioma; SDHB, succinate dehydrogenase subunit B.
